Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gisadenafil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A known ✓ | O76074 | 20/20 | 1.00 |
| ▸ | PDE6C | P51160 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gisadenafil SCHEMBL29379724 | 1.00 | PDE5A (1.00) | PDE5APDE6C | |
| SCHEMBL3579657 | 0.95 | PDE5A (0.91) | PDE5APDE6C | |
| SCHEMBL3576608 | 0.95 | PDE5A (1.00) | PDE5APDE6C | |
| SCHEMBL4559199 | 0.95 | PDE5A (0.90) | PDE5APDE6C | |
| SCHEMBL3584023 | 0.95 | PDE5A (1.00) | PDE5APDE6C | |
| SCHEMBL6767921 | 0.95 | PDE5A (0.90) | PDE5APDE6C | |
| Gisadenafil SCHEMBL6199327 | 0.94 | PDE5A (0.89) | PDE5APDE6C | |
| SCHEMBL3583701 | 0.94 | PDE5A (0.93) | PDE5APDE6C | |
| SCHEMBL3583755 | 0.94 | PDE5A (0.89) | PDE5APDE6C | |
| SCHEMBL3579671 | 0.94 | PDE5A (0.89) | PDE5APDE6C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210060123-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2021-03-04 | — | — | US | claimed |
| US-20180161392-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2018-06-14 | — | — | US | claimed |
| US-20180036314-A1 | METHODS AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE | EXODOS LIFE SCIENCES LP (US) | 2018-02-08 | — | — | US | claimed |
| EP-2825208-B1 | P75NTR NEUROTROPHIN BINDING PROTEIN FOR THERAPEUTIC USE | LEVICEPT LTD (GB) | 2017-05-17 | — | — | EP | claimed |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED) (IE) | 2015-11-12 | — | — | US | claimed |
| US-20150037335-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2015-02-05 | — | — | US | claimed |
| US-20150031704-A1 | METHODS AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE | EXODOS LIFE SCIENCES LIMITED PARTNERSHIP | 2015-01-29 | — | — | US | claimed |
| EP-2825208-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | Levicept Ltd. (GB) | 2015-01-21 | — | — | EP | claimed |
| EP-2175728-B1 | SODIUM CHANNEL INHIBITORS | ICAGEN INC (US) | 2014-09-10 | — | — | EP | claimed |
| WO-2013136078-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2013-09-19 | — | — | WO | claimed |
| EP-1220856-A2 | PYRAZOLO[4,3-D]PYRIMIDINE DERIVATIVES | Pfizer Limited (GB) | 2002-07-10 | — | — | EP | claimed |
| EP-1199070-A2 | Use of PDE V inhibitors for improved fecundity in mammals | Pfizer Limited (GB) | 2002-04-24 | — | — | EP | claimed |
| US-20020040140-A1 | For therapy of male erectile dysfunction | PFIZER INC. | 2002-04-04 | — | — | US | claimed |
| US-20020028799-A1 | Treatment of male sexual dysfunction | PFIZER INC. | 2002-03-07 | — | — | US | claimed |
| US-20020022732-A1 | Novel process for the preparation of pyrazoles | PFIZER INC. | 2002-02-21 | — | — | US | claimed |
| WO-2002010171-A1 | CRYSTALLINE THERAPEUTIC AGENT | PFIZER LIMITED (GB) | 2002-02-07 | — | — | WO | claimed |
| EP-1176142-A1 | Process for the preparation of pyrazoles | PFIZER INC. (US) | 2002-01-30 | — | — | EP | claimed |
| WO-2002003995-A2 | TREATMENT OF MALE SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2002-01-17 | — | — | WO | claimed |
| EP-1157705-A2 | Use of a phosphodiesterase inhibitor in the manufacture of a medicament for blood pressure stabilization during hemodialysis | Pfizer Products Inc. (US) | 2001-11-28 | — | — | EP | claimed |
| WO-2001027113-A2 | PYRAZOLO `4,3-d! PYRIMIDINE DERIVATIVES | PFIZER LIMITED (GB) | 2001-04-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028799-A1 | Treatment of male sexual dysfunction | MME, PDE5A, PREP | PDE5A 2/4885PDE6C 91/4885 |
| US-20020022732-A1 | Novel process for the preparation of pyrazoles | NAT1, CYP2F1, CYP51A1 | PDE5A 1067/4885PDE6C 4116/4885 |
| US-20020040140-A1 | For therapy of male erectile dysfunction | PDE3A, PDE5A, PDE3B | PDE5A 2/4885PDE6C 66/4885 |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | PDE5A 27/4885PDE6C 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.